BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 25074044)

  • 1. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
    Donato MF; Monico S; Malinverno F; Aghemo A; Maggioni M; Reggiani P; Colombo M
    Liver Int; 2015 Jan; 35(1):1-4. PubMed ID: 25074044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
    Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
    Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
    Donato MF; Morelli C; Romagnoli R; Invernizzi F; Mazzarelli C; Iemmolo RM; Montalbano M; Lenci I; Bhoori S; Pieri G; Berardi S; Caraceni P; Martini S;
    Liver Int; 2017 May; 37(5):678-683. PubMed ID: 27865034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
    Gallegos-Orozco JF; Charlton MR
    Liver Int; 2015 Jan; 35(1):9-11. PubMed ID: 25412996
    [No Abstract]   [Full Text] [Related]  

  • 6. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.
    Pellicelli AM; Montalbano M; Lionetti R; Durand C; Ferenci P; D'Offizi G; Knop V; Telese A; Lenci I; Andreoli A; Zeuzem S; Angelico M
    Dig Liver Dis; 2014 Oct; 46(10):923-7. PubMed ID: 24997638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
    Kim B; Trivedi A; Thung SN; Grewal P
    Semin Liver Dis; 2014 Feb; 34(1):108-12. PubMed ID: 24782264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting.
    Londoño MC; Manzardo C; Rimola A; Ruiz P; Costa J; Forner A; Ambrosioni J; Agüero F; Laguno M; Lligoña A; Moreno A; Miró JM
    J Antimicrob Chemother; 2016 Nov; 71(11):3195-3201. PubMed ID: 27402009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
    Price JC; Terrault NA
    Liver Int; 2015 Jan; 35(1):7-8. PubMed ID: 25183500
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
    Martini S; Sacco M; Strona S; Arese D; Tandoi F; Dell Olio D; Stradella D; Cocchis D; Mirabella S; Rizza G; Magistroni P; Moschini P; Ottobrelli A; Amoroso A; Rizzetto M; Salizzoni M; Saracco GM; Romagnoli R
    Liver Int; 2017 Jan; 37(1):62-70. PubMed ID: 27344058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation.
    Gambato M; Lens S; Navasa M; Forns X
    J Hepatol; 2014 Nov; 61(1 Suppl):S120-31. PubMed ID: 25443340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
    Pungpapong S; Aqel B; Leise M; Werner KT; Murphy JL; Henry TM; Ryland K; Chervenak AE; Watt KD; Vargas HE; Keaveny AP
    Hepatology; 2015 Jun; 61(6):1880-6. PubMed ID: 25722203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of hepatitis C infection before and after liver transplantation.
    Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
    World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of HCV transplant patients with triple therapy.
    Coilly A; Roche B; Duclos-Vallée JC; Samuel D
    Liver Int; 2014 Feb; 34 Suppl 1():46-52. PubMed ID: 24373078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
    Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
    Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
    Grant JL; Hawkins C; Brooks H; Palella FJ; Koppe SW; Abecassis MM; Stosor V
    AIDS; 2016 Jan; 30(1):93-8. PubMed ID: 26731756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
    Forns X; Charlton M; Denning J; McHutchison JG; Symonds WT; Brainard D; Brandt-Sarif T; Chang P; Kivett V; Castells L; Prieto M; Fontana RJ; Baumert TF; Coilly A; Londoño MC; Habersetzer F
    Hepatology; 2015 May; 61(5):1485-94. PubMed ID: 25557906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
    Huysentruyt K; Stephenne X; Varma S; Scheers I; Leclercq G; Smets F; Sokal EM
    Liver Transpl; 2017 Apr; 23(4):552-553. PubMed ID: 28006874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.